AP
GILD icon

Arlington Partners’s Gilead Sciences GILD Stock Holding History

Arlington Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23
Closed -$1.72K – 282
2023
Q3 		$1.72K Hold
23
– – ﹤0.01% 280
2023
Q2 		$1.77K Sell
23
-445
-95% -$35.5K ﹤0.01% 541
2023
Q1 		$38.8K Buy
+468
New +$38.8K 0.01% 278
2022
Q3 		– Sell
-1,199
Closed -$74K – 401
2022
Q2 		$74K Buy
1,199
+455
+61% +$28.2K 0.02% 202
2022
Q1 		$44K Hold
744
– – 0.01% 259
2021
Q4 		$54K Sell
744
-1,826
-71% -$126K 0.01% 272
2021
Q3 		$180K Buy
+2,570
New +$181K 0.05% 115
2019
Q2 		– Sell
-117
Closed -$8K – 235
2019
Q1 		$8K Buy
+117
New +$7.78K 0.01% 182

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arlington Partners's GILD Position: Q4 2023 in Review

Arlington Partners sold out of Gilead Sciences (GILD) in Q4 2023, closing a stake of 23 shares — an estimated $1.72K sold.

Arlington Partners first reported a position in GILD in Q1 2019 and held it in 8 quarters. The position peaked at $180K in Q3 2021. 1,775 funds tracked by Wall St. Rank hold GILD as of Q4 2023.

  • Arlington Partners reported no remaining Gilead Sciences position as of Q4 2023 after selling out during the quarter.
  • Arlington Partners sold 23 Gilead Sciences shares in Q4 2023, an estimated $1.72K.
  • Arlington Partners first reported a position in Gilead Sciences in Q1 2019 and held it in 8 quarters.
  • Arlington Partners's Gilead Sciences position peaked at $180K in Q3 2021.
  • 1,775 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2023.

Based on Arlington Partners's 13F filing for Q4 2023, filed 24 Jan 2024.